PlushCare vs Henry Meds: GLP-1 Weight Loss Programs Compared (2026)
An independent, side-by-side comparison of PlushCare and Henry Meds for GLP-1 weight loss programs — pricing, medications, protocols, and patient experience.

Quick Verdict
Best Price
PlushCare
Starting at $99/mo vs $149/mo
Most Medications
PlushCare
2 medications vs 2
Best for Beginners
Henry Meds
Async Telehealth, fast onboarding
Head-to-Head Comparison
Pricing Breakdown
Side-by-side pricing for every medication.
| Medication | PlushCare | Henry Meds | Savings |
|---|---|---|---|
| Semaglutide | $99/monthly | $149/monthly | Save $50/mo with PlushCare |
| Tirzepatide | Not offered | $349/monthly | Only at Henry Meds |
Pros and Cons
PlushCare
- Backed by publicly traded Accolade
- Insurance-based model
- Video consultations with licensed physicians (not async questionnaire reviews)
- Prescriptions filled at your own pharmacy
- Can manage related health conditions in the same visit (primary care model)
- Available in all 50 states
- No compounded medications offered
- Generalist physicians, not obesity medicine specialists
- Low membership cost but consultation fees add up without insurance
- Not focused on weight loss
- No proprietary coaching, behavioral program, or weight-loss-specific support
Henry Meds
- Among the lowest compounded GLP-1 pricing available
- Fast onboarding process (prescriptions within 24-48 hours)
- No consultation fee
- Free shipping included
- Async-only — no video consultations
- No lab testing included
- Relatively new company with limited track record
- Only compounded medications (no brand-name options)
How They Compare
Our editorial assessment across key dimensions.
In-Depth Comparison
By sarah-chen · Last updated April 14, 2026
PlushCare vs Henry Meds: GLP-1 Programs Compared
PlushCare and Henry Meds take different approaches to GLP-1 access. PlushCare is a full-service primary care telehealth platform that prescribes GLP-1 medications as one of many clinical services. Henry Meds is a lean, dedicated GLP-1 and hormone therapy platform optimized for fast access and competitive long-term pricing. Here is how they compare.
Quick Verdict
| PlushCare | Henry Meds | |
|---|---|---|
| Monthly cost | $19/month membership + ~$30 visit + medication separately | $149/month (includes compounded semaglutide or tirzepatide) |
| Best for | Patients wanting primary care + GLP-1 from one provider; insurance users | Patients wanting dedicated GLP-1 at lowest ongoing cash-pay price |
| Insurance accepted | Yes — key differentiator | No |
| Medication | Brand-name via insurance or compounded via telehealth | Compounded semaglutide or tirzepatide |
| Tirzepatide | Limited (brand-name via insurance; limited compounded) | Yes (compounded) |
| Start time | ~5–10 days | ~4–7 days |
| Primary care services | Full — ongoing PCP relationship | No — GLP-1 focused only |
The Model Difference
PlushCare: A subscription telehealth platform offering primary care, urgent care, and specialist consultations. GLP-1 medications are prescribed within this broader clinical relationship. PlushCare accepts most major insurance plans and can prescribe brand-name GLP-1 medications (Wegovy, Ozempic, Zepbound) with insurance authorization.
Henry Meds: Built exclusively for GLP-1 medications and testosterone replacement therapy. No insurance accepted — the model is optimized for low-cost cash-pay access. The clinical team is focused on GLP-1 protocols; the platform handles medication sourcing through 503B compounding pharmacies.
Cost Breakdown
PlushCare
| Component | Cost |
|---|---|
| Monthly membership | $19/month |
| Per-visit fee | ~$30/visit (with membership) |
| Brand-name GLP-1 (with insurance) | Insurance copay (~$0–$50 with savings card) |
| Compounded semaglutide (no insurance) | Separate pharmacy cost (~$100–$150/month) |
| Annual estimate (insurance + low copay) | ~$588/year ($19 × 12 + $300 medication + visits) |
| Annual estimate (no insurance, compounded) | ~$1,800–$2,400/year |
Henry Meds
| Component | Cost |
|---|---|
| Monthly fee (includes medication) | $149/month (months 1–6) |
| Monthly fee after 6 months | $129/month |
| Annual (first year) | ~$1,788 |
| Annual (after first year) | ~$1,548 |
Cost verdict: If PlushCare successfully gets insurance-covered brand-name GLP-1 with a low copay, PlushCare is cheaper. For cash-pay patients, Henry Meds at $129/month (after 6 months) is the lower long-term cost.
Insurance: PlushCare's Key Advantage
PlushCare accepts most major insurance plans and can:
- Submit prior authorizations for Wegovy, Ozempic, Zepbound, Mounjaro
- Work within your existing insurance relationship
- Coordinate with your pharmacy benefit for brand-name dispensing
- Manage coverage appeals if needed
Henry Meds does not accept insurance. For patients with insurance that covers GLP-1 medications, PlushCare opens the brand-name pathway; Henry Meds does not.
Primary Care Integration: PlushCare's Broader Value
PlushCare functions as a primary care provider. For patients who need:
- Ongoing primary care management
- Lab work and metabolic monitoring
- Management of comorbid conditions (diabetes, hypertension, thyroid)
- GLP-1 prescribed within a broader clinical relationship
...PlushCare's value extends well beyond GLP-1 alone. The $19/month membership + per-visit fees covers primary care needs that would otherwise require separate appointments.
Henry Meds does not offer primary care — if you need management of comorbidities or general health issues, you'll need a separate primary care relationship.
Medication Options
| Medication | PlushCare | Henry Meds |
|---|---|---|
| Brand-name Ozempic | Yes (via insurance) | No |
| Brand-name Wegovy | Yes (via insurance) | No |
| Brand-name Zepbound | Yes (via insurance) | No |
| Compounded semaglutide | Limited | Yes |
| Compounded tirzepatide | Limited | Yes |
Henry Meds has clearer access to compounded tirzepatide for cash-pay patients. PlushCare's tirzepatide access is primarily brand-name Zepbound through insurance.
Head-to-Head: Who Should Choose Which
Choose PlushCare if:
- You have insurance that may cover GLP-1 medications
- You want a primary care relationship alongside GLP-1 management
- You need other telehealth services (urgent care, ongoing conditions)
- You want brand-name medication via insurance
- You're comfortable coordinating your own pharmacy
Choose Henry Meds if:
- You're paying cash and want the lowest long-term monthly cost
- Tirzepatide at cash-pay pricing is your preference
- You want a dedicated GLP-1 platform focused exclusively on that treatment
- Speed to first dose matters ($4–7 days)
- You don't need primary care services bundled
Alternatives to Consider
| Provider | Why Consider | Monthly Cost |
|---|---|---|
| Ro | Fast, all-in, tirzepatide, no insurance | $149 |
| Sequence | Insurance navigation specialist | ~$99 + medication |
| FORM Health | Specialist care + insurance | $149+ |
| Sesame | Per-visit marketplace; can use any pharmacy | ~$99–$175 |
Related Resources
- Best GLP-1 Without Insurance — cash-pay platforms ranked
- Best GLP-1 with Insurance — insurance navigation platforms
- PlushCare vs Sesame — another PlushCare comparison
- Best GLP-1 Fast Start — fastest path to first dose
- Henry Meds vs Hims — Henry Meds vs another dedicated GLP-1 platform
Related Guides
Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care
The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.
Read guide →Is Compounded Semaglutide Legal and Safe in 2026?
Is compounded semaglutide still legal? We break down the current FDA rules, 30 new warning letters, SAFE Drugs Act, Hims exiting compounded, and what this means for your prescription.
Read guide →Compounded Tirzepatide 2026: What's Happening and What Patients Should Do
Compounded tirzepatide is under active FDA enforcement as of March 2026 — supply is declining but not yet at zero. The 503B enforcement discretion ended over a year ago (March 2025); the FDA has now issued 50+ warning letters including a 30-letter batch in March 2026. Here's what patients need to know and what to do.
Read guide →